Table 3.
Structural equation models for depressive symptoms, withdrawal-relevant negative affect, craving, general negative affect, and general positive affect.
| Variable/Path | Est | Bias-Corrected 95% CI | StdXY | χ2 (df) | p-value | RMSEA (90% CI) | Prob. ≤ .05 | CFI | WRMR |
|---|---|---|---|---|---|---|---|---|---|
| Depressive Symptoms | |||||||||
| Pre-quit slope on fluoxetine (as) | −0.563 | (−1.343, 0.187) | −0.260 | 3.64 (6) | 0.725 | 0.000 (0.000, 0.066) | 0.893 | 1.000 | 0.260 |
| TQD abst on pre-tx intercept (bi) | −0.039 | (−0.081, 0.811) | −0.233 | ||||||
| TQD abst on pre-quit slope (bs) | −0.474 | (−35.64, −0.183)** | −0.498 | ||||||
| TQD abst on FTND | −0.157 | (−1.893, −0.055)* | −0.317 | ||||||
| TQD abst on fluoxetine (c′) | −0.266 | (−18.207, 0.146) | −0.130 | ||||||
| Withdrawal-Relevant Negative Affect | |||||||||
| Pre-quit slope on fluoxetine (as) | −0.069 | (−0.118, −0.019)** | −0.270 | 22.38 (23) | 0.497 | 0.000 (0.000, 0.056) | 0.916 | 1.000 | 0.539 |
| TQD abst on pre-tx intercept (bi) | −0.740 | (−1.319, −0.058)* | −0.284 | ||||||
| TQD abst on pre-quit slope (bs) | −3.717 | (−7.136, −1.480)** | −0.465 | ||||||
| TQD abst on FTND | −0.107 | (−0.208, −0.018)** | −0.217 | ||||||
| TQD abst on fluoxetine (c′) | −0.257 | (−0.690, 0.154) | −0.125 | ||||||
| Cravinga | |||||||||
| Pre-quit slope on fluoxetine (as) | −0.054 | (−0.109, −0.004)* | −0.233 | 23.01 (23) | 0.520 | 0.000 (0.000, 0.054) | 0.924 | 1.000 | 0.560 |
| TQD abst on pre-tx intercept (bi) | 0.771 | (0.019, 3.934)* | 0.320 | ||||||
| TQD abst on pre-quit slope (bs) | −4.345 | (−12.40, −1.566)** | −0.488 | ||||||
| TQD abst on FTND | −0.249 | (−0.618, −0.120)** | −0.503 | ||||||
| Pre-tx intercept on FTND | 0.119 | (0.082, −0.153)** | 0.581 | ||||||
| TQD abst on fluoxetine (c′) | −0.234 | (−0.879, 0.235) | −0.114 | ||||||
| General Negative Affectb | |||||||||
| Pre-quit slope (linear) on fluoxetine (as) | −0.209 | (−1.194, 1.135) | −0.168 | 18.63 (17) | 0.350 | 0.022 (0.000, 0.068) | 0.800 | 0.995 | 0.494 |
| Pre-quit slope (curv) on fluoxetine (ac) | −0.030 | (−0.396, 0.243) | −0.058 | ||||||
| TQD abst on pre-tx intercept (bi) | −0.119 | (−0.715, −0.032)** | −0.525 | ||||||
| TQD abst on pre-quit slope (linear) (bs) | −1.704 | (−8.376, −0.499)** | −1.236 | ||||||
| TQD abst on pre-quit slope (curv) (bc) | −0.165 | (−2.920, 5.157) | −0.024 | ||||||
| TQD abst on FTND | −0.283 | (−2.226, −0.151)** | −0.647 | ||||||
| TQD abst on fluoxetine (c′) | −0.349 | (−6.828, 0.349) | −0.209 | ||||||
| General Positive Affect c | |||||||||
| Pre-quit slope on fluoxetine (as) | 0.196 | (−0.518, 0.939) | 0.057 | 29.88 (23) | 0.153 | 0.038 (0.000, 0.073) | 0.674 | 0.970 | 0.599 |
| TQD abst on pre-tx intercept (bi) | 0.043 | (0.007, 0.079)* | 0.260 | ||||||
| TQD abst on pre-quit slope (bs) | 0.115 | (−0.078, 0.292) | 0.193 | ||||||
| TQD abst on FTND | −0.104 | (−0.119, −0.021)** | −0.201 | ||||||
| TQD abst on fluoxetine (c′) | −0.022 | (−0.408, 0.335) | −0.011 | ||||||
P < 0.05,
P < 0.00.
TQD: target quit date; pre-tx: pre-treatment; FTND: Fagerström Test for Nicotine Dependence; Est: estimate; SE: standard error; CI: confidence interval; stdXY: fully standardized; RMSEA: root mean square error of approximation; CFI: Comparative Fit Index; WRMR: weighted root mean square residual.
Note: Pre-treatment intercepts for all variables were not significantly associated with gender (not presented in the table). Gender and FTND were included as covariates, predicting pre-treatment intercepts and pre-quit slope as well as TQD abstinence in all models; however, only significant relationships are presented here (gender was not related to intercept, slope, or TQD abstinence in any models).
The association between baseline nicotine dependence levels and pre-treatment intercept for each variable was estimated in each model (not presented in the table).
The linear growth models for all but general negative affect had adequate-to-good model fit. A quadratic growth model for general negative affect was estimated and the model fitted the data well. Baseline nicotine dependence was significantly associated only with pre-treatment intercept of craving.
The pre-treatment intercept and slope of were significantly correlated only in the positive affect model.